



**SigmaGraft**

BIOMATERIALS



**InterOss<sup>®</sup>**

Anorganic Cancellous Bone Granules

# InterOss®

## Anorganic Cancellous Bone Granules



InterOss® is a natural hydroxyapatite bone grafting material for use in dentistry. Made from a proven multi-step purification process which leaves only a bone composition, it is a highly purified osteoconductive material for bone regeneration.


Having an interconnected network of macro and micro pores and large inner surface areas that provides an ideal environment for cell attachment, InterOss® is chemically and structurally comparable to mineralized human bone. It is available in sterilized granule form and is dedicated for single uses.

### Osteoconductive

A preclinical trial was conducted to treat 54 mandibular critical-sized alveolar ridge defects in 27 canines. The study confirmed InterOss® osteoconductivity as it was clinically and histologically successful in forming new bone.


#### At 4 weeks:

Residual material with some woven bone formation (N) was observed.




#### At 8 weeks:

A significant amount of new bone formation (N) was observed.



#### At 12 weeks:

A mixture of mature and woven bone formation (N) was observed.



### Indications for Use

InterOss® is recommended for:

- Augmentation or reconstructive treatment of the alveolar ridge including the filling of extraction sockets
- Filling of infrabony periodontal defects
- Filling of defects after root resection, apicoectomy, and cystectomy
- Elevation of the maxillary sinus floor
- Filling of periodontal defects in conjunction with products intended for guided tissue regeneration (GTR) and guided bone regeneration (GBR)
- Filling of peri-implant defects in conjunction with products intended for guided bone regeneration (GBR)

### Available in the following options

#### Small Granules (0.25 - 1.0 mm)

VIAL	Volume	Weight	SYRINGE	Volume
IOSG025	0.54 cc	0.25 g	IOSGS025	0.25 cc
IOSG050	1.08 cc	0.5 g	IOSGS050	0.5 cc
IOSG100	2.16 cc	1.0 g	IOSGS100	1.0 cc
IOSG200	4.32 cc	2.0 g		


#### Large Granules (1.0 - 2.0 mm)

VIAL	Volume	Weight	SYRINGE	Volume
IOLG050	2.0 cc	0.5 g	IOLGS050	0.5 cc
IOLG100	4.0 cc	1.0 g	IOLGS100	1.0 cc
IOLG200	8.0 cc	2.0 g		

### Features & Benefits

#### Biocompatible

Highly purified bone mineral resulting from a long annealing process. A plateau region observed in the Thermogravimetric Analysis curve below shows extremely low residual organic substances.



#### Micro & Macro Porous

- Porosity enhances osteogenesis and promotes attachment and proliferation of bone forming cells
- Microporosity facilitates proliferation of osteoblasts
- Macroporosity allows vascularization and plays important role in the osteoconductivity

### A Comparison Study with Bio-Oss®

■ InterOss® ■ Product B




Figure 1, Histomorphometry  
Percent Bone by Area (BA/DA)

While not statistically different, on average InterOss® had more than twice the mean amount of bone present at 8 and 12 weeks (8.88% and 14.76%, respectively) as compared to Product B (3.58% and 7.54%, respectively).




Figure 2, Histomorphometry  
Percent Residual Graft by Area (GA/DA)

Overall, both InterOss® and Product B were very similar throughout the study; no statistical differences in percent residual graft were observed between the two treatment groups. At 12 weeks, the values were 5.78% for InterOss® and 4.43% for Product B.




Figure 3, Histomorphometry  
Bone Formation Density (BA/BMA)

Bone formation density is the ratio of newly formed bone to newly formed bone marrow area and can be used to understand bone formation densities.

## Application & Handling

### Hydration

InterOss® can be hydrated in blood or sterile saline solution.

### Wound Closure

Ensure that the grafted site is securely closed with the soft tissue free of tension.

### Healing Time and Re-entry

Healing time depends on the patient, nature and the size of the defect site and thus must be determined by the clinician based on the initial diagnosis. For a safe re-entry, it is recommended to let the surgical site heal for at least six months to ensure the graft material has been integrated properly.

### For Use with Allograft

The long-term stability of InterOss® coupled with the

biological potential of allograft may yield enhanced bone regeneration.

### For Use with Autologous Bone

InterOss® helps achieve a natural biological activity due to the osteoinductivity and osteogenesis of autologous bone which in turn may encourage faster regeneration.




### Application

- InterOss® can be administered to the surgical site after hydration using a surgical curette or periosteal elevator.
- For maximum results, the graft material should make sufficient contact with the bleeding bone surface to facilitate ingrowth of new blood vessels and bone forming cells.
- A resorbable membrane should be used in conjunction with the graft material by placing over it to minimize particulate migration

## Properties

Attribute	Description
Composition	Calcium phosphate (100% pure hydroxyapatite, mineral phase)
Integration time	6 - 9 months (depending on defect)
Storage temperature	59 - 77 °F / 15 - 25 °C
Degradation profile	Bovine hydroxyapatite provides osteoconductive surface enabling a slow degradation and enhanced osseointegration of particles into a new bone.

*The existence of mesopores and micropores in the granules increases the inner surface area enhancing osteoconduction thus encouraging bone growth inside the pores.*



## Immediate Bone Grafting on a Compromised Maxillary Molar Site Restores Alveolar Ridge Width and Height

Dr. David M. Kim

Boston, MA

United States

### Patient History

A 38-year-old healthy female patient presented with a missing single FPD on the upper left first molar.

### Conclusion


The tooth was extracted due to poor prognosis, and ridge preservation was performed using InterOss® and a collagen membrane. At 5 months, sufficient bone regeneration allowed implant placement. The 7-year follow-up demonstrated stable bone and healthy soft tissue, confirming long-term success of the ARP procedure.



Pre-operative view.



A view of the bone defect.




The buccal view revealed vertical bone loss.



InterOss® placement.



Membrane placement and post-operative view.



Post-operative view at 5 months.



Implant placement.



Implant crown restoration.

## Vertical Ridge and Sinus Augmentation in the Posterior Maxilla with InterOss

Dr. Alberto Monje  
 University of Michigan, United States  
 Universitat Internacional de Catalunya, Spain

### Patient History


A healthy, non-smoking, partially edentulous patient presented with a severely atrophic posterior maxilla, seeking oral rehabilitation. The patient had no significant medical history and expressed a desire for a fixed dental

### Conclusion


Sinus floor elevation and vertical ridge augmentation using InterOss and autogenous bone were performed simultaneously with the tent-pole technique. After uneventful healing, implants were placed with good stability. At 3 years, outcomes showed healthy peri-implant tissue and high patient satisfaction.




Pre-operative view.



A view of the bone defect.



Membrane placement.



InterOss® placement.



Post-operative view.



Implant placement.



Follow-up at 3 years..



Post-operative X-ray at 3 years.

## Combined Resective-reconstructive Therapy of Peri-implantitis

Dr. Riccardo di Gianfilippo  
 University of Michigan  
 United States

### Patient History


The patient had 10 mm of peri-implant bone loss, with signs of inflammation and soft-tissue recession. They reported occasional discomfort and bleeding, with suboptimal oral hygiene and no recent trauma.

### Conclusion

InterOss® was placed in a peri-implant infrabony defect and covered with a flap, without using a membrane. The material integrated well, supporting stable healing and soft-tissue closure. Its ease of use and compatibility make it a reliable option for similar cases.



Pre-operative view.



Pre-operative X-ray.




10mm peri-implant bone loss.



InterOss® placement.



Follow-up at 6 months.



X-ray at 6 months.



Gingival graft.



Follow-up at 2 weeks and 3 months after FG.



**SigmaGraft**  
MADE IN USA 



**SigmaGraft, Inc. Headquarters**

575 Sally Place  
Fullerton, CA 92831  
United States  
[www.SigmaGraft.com](http://www.SigmaGraft.com)

**USA Branch**

450 Apollo St Ste B  
Brea, CA 92821  
United States

P: 888 499 0114 (toll free)

714 525 0114

F: 714 525 0116

E: [info@sigmagraft.com](mailto:info@sigmagraft.com)

SCIENCE THAT NURTURES WELLNESS